Pharma M&As set to continue
With Merck looking to sell off its generic pharma business, 2007 appears set to continue with consolidation, which has been the buzzword for the $100-billion global generic pharmaceutical business, in recent times.
By Vivek Sinha, TNN |
NEW DELHI: With Merck looking to sell off its generic pharma business, 2007 appears set to continue with consolidation, which has been the buzzword for the $100-billion global generic pharmaceutical business, in recent times.
The end game is economies of scale in manufacturing, which brings down production costs, less competition and arguably more pricing power in what is otherwise a highly fragmented and competitive, but lucrative growth market.
At the top deck, the two global giants Teva and Sandoz, the generic business wing of Novartis, have been playing a cat and mouse game for the number one spot over the last couple of years.
vivek.sinha@timesgroup.com
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
